First-line (1L) immuno-oncology (10) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).-MedSci.cn

First-line (1L) immuno-oncology (10) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).

Dudani, S; Graham, J; Wells, C; Bakouny, Z; Pal, SK; Dizman, N; Donskov, F; Porta, C; de Velasco, G; Hansen, AR; Iafolla, MAJ; Beuselinck, B; Vaishampayan, UN; Wood, L; Liow, ECH; Yan, F; Yuasa, T; Bjarnason, GA; Choueiri, TK; Heng, DYC

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务